Total raised
$91.0M
Last: PIPE 2026-02
Stage
Mature
Founded
2004
Headcount
62
HQ
Rehovot
Sector
Health Tech & Life Sciences
About
CollPlant is a regenerative and aesthetic medicine company developing technologies and products for tissue regeneration and organ manufacturing.
Its revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, CollPlant is developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.
Funding history · 14 rounds · $91.0M total
2026-02
PIPE
$2.0M
2025-05
PIPE
$3.6M
2021-02
PIPE
$35.0M
2020-02
PIPE
$4.5M
2019-09
PIPE
$5.5M
2017-11
PIPE
$7.4M
2017-09
PIPE
$5.0M
2013-10
Undisclosed
$2.5M
2012-11
PIPE
$2.8M
2012-02
PIPE
$1.0M
2008-04
Undisclosed
$8.3M
2007-04
Undisclosed
$4.5M
2007-02
Undisclosed
$2.0M
2006-09
Undisclosed
$1.5M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is CollPlant's primary focus in the medical field?
- CollPlant is a regenerative and aesthetic medicine company that develops technologies and products for tissue regeneration and organ manufacturing.
- What is CollPlant's core technology?
- CollPlant's core technology is a plant-based method for the mass production of recombinant human Type I collagen (rhCollagen), which is identical to human-produced collagen.
- When did CollPlant become a publicly traded company on NASDAQ?
- CollPlant became public on NASDAQ in December 2010.
- What was a significant partnership announced by CollPlant in October 2018?
- In October 2018, CollPlant announced a global licensing and commercialization agreement with United Therapeutics for 3D bioprinting of solid-organ scaffolds for human transplants.
- What product distribution agreement did CollPlant renew in March 2019?
- In March 2019, CollPlant renewed its distribution agreement for its soft tissue repair product, Vergenix™STR, with Arthrex.
- What collaboration did CollPlant announce in January 2020?
- In January 2020, CollPlant Biotechnologies joined forces with 3D Systems to accelerate breakthroughs in regenerative medicine.
- What significant development and commercialization agreement did CollPlant announce in February 2021?
- In February 2021, CollPlant announced a development and global commercialization agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen in dermal and soft tissue filler products.
- What was the outcome of a preclinical study for 3D bioprinted regenerative breast implants in January 2023?
- In January 2023, CollPlant announced successful preclinical results in a porcine study for 3D bioprinted regenerative breast implants, achieving all objectives.
- What was a key finding from a study conducted by Technion – Israel Institute of Technology in October 2025?
- In October 2025, a study by Technion – Israel Institute of Technology found that CollPlant's rhCollagen-based bioink, Collink.3D™, demonstrated strong performance, outperforming Matrigel®.
- What new product did CollPlant launch in February 2026 to enhance its 3D bioprinting portfolio?
- In February 2026, CollPlant launched Ready-to-Print BioFlex, elevating its rhCollagen 3D Bioprinting Portfolio.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenesMachinery & Robotics3D Printing & Additive Manufacturing
Target customers
Healthcare & Life SciencesHealthcareProvidersLife SciencesPharmaceuticals
Business model
B2B
Highlights
Verified
Tags
orthopedicsregenerative-medicinebiomaterialstissue-regenerationpharmaceuticalstreatmentsmedical-devicesnanotechnology3d-technologydrug-deliverymedical-productsmedical-technologies